



DUOPHARMA BIOTECH BERHAD

**ANTI-MONEY LAUNDERING AND
COUNTER FINANCING TERRORISM
POLICY**

DOCUMENT NO: DBB/GRMI/POL/002-03

REVISION NO: 03

EFFECTIVE DATE : 7 FEBRUARY 2020
REVISION DATE : 8 NOVEMBER 2023



ANTI-MONEY LAUNDERING AND COUNTER FINANCING TERRORISM POLICY

1. INTRODUCTION

Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) is committed to achieving the highest standards of ethical conduct and complying with all applicable laws in the countries where it conducts business.

Anti-money laundering provisions are designed to help prevent legitimate businesses from being used by criminals for this purpose, and to assist law enforcement agencies to trace and recover criminal assets and terrorist funding.

This Policy applies to all Directors, Officers and Employees (permanent and temporary) of Duopharma Biotech, subsidiaries and affiliated companies, regardless of the location of employment.

2. DEFINITION

Money laundering is a process of converting cash or property derived from criminal activities to give it a legitimate appearance. It is a process to clean ‘dirty’ money in order to disguise its criminal origin. (*source: amlctf.bnm.gov.my*)

Terrorism financing is the act of providing financial support, funded from either legitimate or illegitimate source, to terrorist or terrorist organisations to enable them to carry out terrorists acts or will benefit any terrorist organisation. Whilst most of the funds originate from criminal activities, they may also be derived from legitimate sources, for example, through salaries, revenues generated from legitimate business or the use of non-profit organisations to raise funds through donation. (*source: amlctf.bnm.gov.my*)

3. GUIDELINES

Duopharma Biotech is required to comply with the requirement under Anti-Money Laundering, Anti-Terrorism Financing Proceeds of Unlawful Activities Act 2001 (AMLATFPUAA 2001) that is governed by Bank Negara Malaysia. Duopharma Biotech recognizes the importance of preventing money laundering, and therefore will comply with international and domestic laws and establish appropriate procedures.

3.1 Customer Due Diligence

Duopharma Biotech will implement and maintain appropriate measures to conduct customer due diligence.

3.2 Risk Assessment

Duopharma Directors, Officers and Employees are expected to be mindful of the risk of the Company's business being use for money laundering activities and to raise any suspicious transactions to their immediate superior and the Board to undertake further investigation.

A risk-based assessment should be carried out to profile the risk related with the respective customers and that proper controls are in place in managing the identified risks proportionate to the nature, scale and complexity of the business activities. Among the activities includes assessment of the client and the company, the product and/or services offered and the geographical location of the customer. New red flags and control measures should be communicated to the Chief Legal Officer and the Management for further action.

3.3 Reporting of Suspicious Transactions

Duopharma Biotech will implement and maintain measures for handling suspicious transactions, and will submit a Suspicious Transaction Report (STR) to Financial Intelligence and Enforcement Department (FIED) of Bank Negara Malaysia whenever the transaction has triggered the suspicion criteria.

3.4 Employee Awareness Program

Duopharma Biotech will conduct awareness programs in matters related to prevention of money laundering so that the relevant personnel can implement immediate and appropriate measures for customer due diligence.

-End of Document -